Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Interest & Investment Income (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Interest & Investment Income readings, the most recent being $833000.0 for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 41.17% to $833000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 38.65% decrease, with the full-year FY2025 number at $3.3 million, down 38.65% from a year prior.
  • Interest & Investment Income hit $833000.0 in Q4 2025 for Amicus Therapeutics, roughly flat from $829000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.2 million in Q1 2023 to a low of $50000.0 in Q2 2021.
  • Median Interest & Investment Income over the past 5 years was $838000.0 (2025), compared with a mean of $966750.0.
  • Biggest five-year swings in Interest & Investment Income: crashed 94.22% in 2021 and later skyrocketed 1553.38% in 2023.
  • Amicus Therapeutics' Interest & Investment Income stood at $186000.0 in 2021, then skyrocketed by 960.22% to $2.0 million in 2022, then decreased by 15.26% to $1.7 million in 2023, then fell by 15.26% to $1.4 million in 2024, then crashed by 41.17% to $833000.0 in 2025.
  • The last three reported values for Interest & Investment Income were $833000.0 (Q4 2025), $829000.0 (Q3 2025), and $843000.0 (Q2 2025) per Business Quant data.